10:42 AM EST - Cardiol Therapeutics Inc. : Announced that the U.S. Food and Drug Administration (FDA) has provided clearance to proceed with the Company's Investigational New Drug (IND) application to commence a Phase II, multi-center, double-blind, randomized, placebo-controlled trial designed to study the safety and tolerability of CardiolRx™, as well as its impact on myocardial recovery in patients presenting with acute myocarditis. Cardiol Therapeutics Inc.
shares T.CRDL are trading up $0.13 at $3.94.
